Diagnostic accuracy of <Superscript>18</Superscript>F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative <Superscript>131</Superscript>I whole body scan: evaluation by thyroglobulin level

Background  

To evaluate the diagnostic accuracy of ¹⁸F-FDG PET/CT in detection of recurrent differentiated thyroid cancer (DTC) in patients with elevated stimulated thyroglobulin (Tg) or anti-Tg antibody (Ab) levels, and negative ¹³¹I whole body scan according to the Tg level.     

Evaluation of (111)In-labeled macrocyclic chelator-amino acid derivatives for cancer imaging

PurposeWe evaluated new ¹¹¹In-labeled amino acid derivatives, in which the amino acids are conjugated with1,4,7,10-tetra-azacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7,10-tetraazacyclododecane-1,7-diacetic acid (DO2A) or 1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid (DO3A).MethodsDOTA-aminoalanine (DOTA-A), DOTA-aminohomoalanine (DOTA-H), DOTA-lysine (DOTA-L), DO2A-alanine (DO2A-A), DO3A-alanine (DO3A-A) and DO3A-homoalanine (DO3A-H) were labeled with ¹¹¹In. In vitro cell uptake assays were performed usingHep3B (a human hepatoma cell line), CT26 (a mouse colon cancer cell line) and U87MG (a human glioma cell line). In vitro cell uptake inhibition assays were performed using U87MG and ¹¹¹In-DO3A-H. U87MG bearing xenografted mice were subject to biodistribution, SPECT imaging, autoradiography, and immunohistochemistry studies.ResultsOf the amino acid derivatives and cell lines examined, U87MG and ¹¹¹In-DO3A-H showed highest uptake in vitro. This uptake was blocked by 2-aminobicyclo-[2,2,1] heptane-2-carboxylic acid (BCH) and by tryptophan. ¹¹¹In-DO3A-HSPECT imaging of U87MG bearing xenografted mice visualized tumors (mean tumor-to-muscle ratio 3.16±0.74). Autoradiography and immunohistochemistry revealed that ¹¹¹In-DO3A-H uptake matched L-type amino acid transporter 1 expression.ConclusionTumor uptake was successfully imaged using ¹¹¹In-DO3A-H in U87MG bearing xenografted mice. ¹¹¹In-DO3A-H appears to be useful for imaging tumors expressing L-type amino acid transporter.     

Cross-cultural adaptation and validation of the Korean version of the Oxford shoulder score

Background  

The Oxford shoulder score (OSS) is being used increasingly and has been adapted cross-culturally in some Western countries. On the other hand, there are few validated translations of the OSS in Asian countries. This study translated and adapted cross-culturally the original OSS to produce a Korean version, and assessed the validity and reliability of the Korean version of the OSS (Korean OSS).     

Renal transplantation in sensitized recipients with positive luminex and negative CDC (complement‐dependent cytotoxicity) crossmatches

Recently, Luminex‐crossmatch (LumXm) was introduced. The aim of this study was to evaluate clinical outcomes in sensitized recipients with a positive Luminex‐crossmatch (LumXm (+)) and a negative complement‐dependent cytotoxicity crossmatch (CDCXm (?)) after renal transplantation. Fifty‐five renal transplant recipients with a CDCXm (?) and PRA class I or II ≥20% were enrolled in this study between February 2008 and December 2010 at Severance Hospital. Eighteen patients displayed LumXm (+) defined as LumXm positive class I or II and 37 patients displayed LumXm (?). Mean duration of follow‐up was 18.9 ± 8.3 months. During this period, no patient death or graft loss occurred. The incidence of biopsy‐proven or clinically presumed rejection was higher in the LumXm (+) group (n = 12, 66.7%) than in the LumXm (?) group (n = 6, 18.2%) (P = 0.001). All biopsy‐proven acute rejections (n = 12) were diagnosed as acute cellular rejection. No significant difference in mean serum creatinine level or eGFR was observed between the groups at 18 months post‐transplantation. The short‐term outcome of renal transplantation in sensitized patients with a LumXm (+) and a CDCXm (?) may be considered to be acceptable. However, patients with a LumXm (+) have a substantially higher immunological risk for the development of acute cellular rejection.     

Primary pericardial spindle cell sarcoma mimicking left main coronary artery disease

Primary spindle cell sarcoma in the heart is a very uncommon disease. Although primary atrial or pulmonary vein spindle cell sarcomas have been sporadically reported, pericardial spindle cell sarcoma is rarely seen in currently available data. The commentary here is on a primary pericardial spindle cell sarcoma that was preliminarily misjudged to be left main coronary artery disease.